Serum trypsin‐like immunoreactivity in dogs with diabetes mellitus

Abstract Background Concurrent exocrine pancreatic dysfunction and decreased pancreatic organ size are common findings in various stages of human type 1 diabetes mellitus (DM). Exocrine pancreatic insufficiency (EPI) is incompletely described in diabetic dogs. Objective To compare canine trypsin‐lik...

Full description

Bibliographic Details
Main Authors: Kristen Hamilton, Allison L. O'Kell, Chen Gilor
Format: Article
Language:English
Published: Wiley 2021-07-01
Series:Journal of Veterinary Internal Medicine
Subjects:
dog
Online Access:https://doi.org/10.1111/jvim.16208
id doaj-e986f21ca5a44de0933ca973886af49b
record_format Article
spelling doaj-e986f21ca5a44de0933ca973886af49b2021-07-22T08:15:50ZengWileyJournal of Veterinary Internal Medicine0891-66401939-16762021-07-013541713171910.1111/jvim.16208Serum trypsin‐like immunoreactivity in dogs with diabetes mellitusKristen Hamilton0Allison L. O'Kell1Chen Gilor2Small Animal Hospital College of Veterinary Medicine, University of Florida Gainesville Florida USADepartment of Small Animal Clinical Sciences College of Veterinary Medicine, University of Florida Gainesville Florida USADepartment of Small Animal Clinical Sciences College of Veterinary Medicine, University of Florida Gainesville Florida USAAbstract Background Concurrent exocrine pancreatic dysfunction and decreased pancreatic organ size are common findings in various stages of human type 1 diabetes mellitus (DM). Exocrine pancreatic insufficiency (EPI) is incompletely described in diabetic dogs. Objective To compare canine trypsin‐like immunoreactivity (cTLI) of diabetic dogs with that of healthy controls. A secondary aim was to evaluate the correlation between duration of DM and cTLI. Animals Thirty client‐owned diabetic dogs and thirty client‐owned control dogs. Methods Cross‐sectional study. Diabetic and healthy control dogs were included if they had no clinical evidence of pancreatitis and if serum samples obtained after food was withheld were available. Serum cTLI was measured at a reference laboratory and compared between groups. Canine pancreatic lipase immunoreactivity (cPLI) was analyzed concurrently as an indicator of pancreatitis. Results The median cTLI concentration in all diabetic dogs (36.4 μg/L [range, 7.0‐288 μg/L]) did not differ from control dogs (28.7 μg/L [range, 12.8‐58.6 μg/L]) (P = .07; difference −7.8 μg/L [95% Confidence Interval (CI), −23.5 to 0.6 μg/L]). There was still no difference in cTLI between groups after exclusion of dogs with cPLI consistent with pancreatitis (n = 8 diabetic dogs). There was no correlation between cTLI and DM duration in all diabetic dogs (r = −0.07, [95% CI, −0.43 to 0.3], P = .7). Conclusions and Clinical Importance There was no evidence of EPI as evaluated using cTLI in this cohort of diabetic dogs, but concurrent increases in cPLI suggest cTLI might not be the optimal indicator of exocrine pancreatic dysfunction in dogs with DM.https://doi.org/10.1111/jvim.16208dogpancreatic lipase immunoreactivitypancreatitistrypsin‐like immunoreactivity
collection DOAJ
language English
format Article
sources DOAJ
author Kristen Hamilton
Allison L. O'Kell
Chen Gilor
spellingShingle Kristen Hamilton
Allison L. O'Kell
Chen Gilor
Serum trypsin‐like immunoreactivity in dogs with diabetes mellitus
Journal of Veterinary Internal Medicine
dog
pancreatic lipase immunoreactivity
pancreatitis
trypsin‐like immunoreactivity
author_facet Kristen Hamilton
Allison L. O'Kell
Chen Gilor
author_sort Kristen Hamilton
title Serum trypsin‐like immunoreactivity in dogs with diabetes mellitus
title_short Serum trypsin‐like immunoreactivity in dogs with diabetes mellitus
title_full Serum trypsin‐like immunoreactivity in dogs with diabetes mellitus
title_fullStr Serum trypsin‐like immunoreactivity in dogs with diabetes mellitus
title_full_unstemmed Serum trypsin‐like immunoreactivity in dogs with diabetes mellitus
title_sort serum trypsin‐like immunoreactivity in dogs with diabetes mellitus
publisher Wiley
series Journal of Veterinary Internal Medicine
issn 0891-6640
1939-1676
publishDate 2021-07-01
description Abstract Background Concurrent exocrine pancreatic dysfunction and decreased pancreatic organ size are common findings in various stages of human type 1 diabetes mellitus (DM). Exocrine pancreatic insufficiency (EPI) is incompletely described in diabetic dogs. Objective To compare canine trypsin‐like immunoreactivity (cTLI) of diabetic dogs with that of healthy controls. A secondary aim was to evaluate the correlation between duration of DM and cTLI. Animals Thirty client‐owned diabetic dogs and thirty client‐owned control dogs. Methods Cross‐sectional study. Diabetic and healthy control dogs were included if they had no clinical evidence of pancreatitis and if serum samples obtained after food was withheld were available. Serum cTLI was measured at a reference laboratory and compared between groups. Canine pancreatic lipase immunoreactivity (cPLI) was analyzed concurrently as an indicator of pancreatitis. Results The median cTLI concentration in all diabetic dogs (36.4 μg/L [range, 7.0‐288 μg/L]) did not differ from control dogs (28.7 μg/L [range, 12.8‐58.6 μg/L]) (P = .07; difference −7.8 μg/L [95% Confidence Interval (CI), −23.5 to 0.6 μg/L]). There was still no difference in cTLI between groups after exclusion of dogs with cPLI consistent with pancreatitis (n = 8 diabetic dogs). There was no correlation between cTLI and DM duration in all diabetic dogs (r = −0.07, [95% CI, −0.43 to 0.3], P = .7). Conclusions and Clinical Importance There was no evidence of EPI as evaluated using cTLI in this cohort of diabetic dogs, but concurrent increases in cPLI suggest cTLI might not be the optimal indicator of exocrine pancreatic dysfunction in dogs with DM.
topic dog
pancreatic lipase immunoreactivity
pancreatitis
trypsin‐like immunoreactivity
url https://doi.org/10.1111/jvim.16208
work_keys_str_mv AT kristenhamilton serumtrypsinlikeimmunoreactivityindogswithdiabetesmellitus
AT allisonlokell serumtrypsinlikeimmunoreactivityindogswithdiabetesmellitus
AT chengilor serumtrypsinlikeimmunoreactivityindogswithdiabetesmellitus
_version_ 1721291696606543872